Huang Cong, Zhuo Fan, Guo Yang, Wang Siyu, Zhang Kaoyuan, Li Xiahong, Dai Wenkui, Dou Xia, Yu Bo
Department of Dermatology, Skin Research Institute of Peking University Shenzhen Hospital, Peking University Shenzhen Hospital, Shenzhen, China.
Shenzhen Key Laboratory for Translational Medicine of Dermatology, Shenzhen Peking University - the Hong Kong University of Science and Technology Medical Center, Shenzhen, China.
Front Cell Infect Microbiol. 2025 Jan 14;14:1518811. doi: 10.3389/fcimb.2024.1518811. eCollection 2024.
Atopic dermatitis (AD) is a chronic and inflammatory skin disorder characterized by impaired barrier function and imbalanced immunity. Recent advances have revealed that dysbiosis of skin microbiota plays important roles in the pathogenesis and development of AD. Meanwhile, endogenous and external factors contribute to the dysbiosis of skin microbiota in AD. Additionally, various treatments, including topical treatments, phototherapy, and systemic biologics, have demonstrated positive impacts on the clinical outcomes, alongside with the modulations of cutaneous microbiota in AD patients. Importantly, therapeutics or products regulating skin microbiota homeostasis have demonstrated potential for AD treatment in early clinical studies. In this review, we underline changes of the skin microbiota correlated with AD. Meanwhile, we provide an overview of the skin microbiota regarding its roles in the pathogenesis and development of AD. Finally, we summarize therapeutic strategies restoring the skin microbial homeostasis in AD management.
特应性皮炎（AD）是一种慢性炎症性皮肤病，其特征是屏障功能受损和免疫失衡。最近的研究进展表明，皮肤微生物群的失调在AD的发病机制和发展中起重要作用。同时，内源性和外源性因素导致了AD患者皮肤微生物群的失调。此外，包括局部治疗、光疗和全身性生物制剂在内的各种治疗方法，已证明对临床结果有积极影响，同时也对AD患者的皮肤微生物群产生了调节作用。重要的是，在早期临床研究中，调节皮肤微生物群稳态的治疗方法或产品已显示出治疗AD的潜力。在这篇综述中，我们强调了与AD相关的皮肤微生物群的变化。同时，我们概述了皮肤微生物群在AD发病机制和发展中的作用。最后，我们总结了在AD管理中恢复皮肤微生物稳态的治疗策略。
